GIA
VTGN icon

Goodwin Investment Advisory’s VistaGen Therapeutics VTGN Stock Holding History

Goodwin Investment Advisory’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-33
Closed -$2K – 147
2020
Q4 		$2K Buy
+33
New +$842 ﹤0.01% 83

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Goodwin Investment Advisory's VTGN Position: Q1 2021 in Review

Goodwin Investment Advisory sold out of VistaGen Therapeutics (VTGN) in Q1 2021, closing a stake of 33 shares — an estimated $2K sold.

Goodwin Investment Advisory first reported a position in VTGN in Q4 2020 and held it in 1 quarter. The position peaked at $2K in Q4 2020. 74 funds tracked by Wall St. Rank hold VTGN as of Q1 2021.

  • Goodwin Investment Advisory reported no remaining VistaGen Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Goodwin Investment Advisory sold 33 VistaGen Therapeutics shares in Q1 2021, an estimated $2K.
  • Goodwin Investment Advisory first reported a position in VistaGen Therapeutics in Q4 2020 and held it in 1 quarter.
  • Goodwin Investment Advisory's VistaGen Therapeutics position peaked at $2K in Q4 2020.
  • 74 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2021.

Based on Goodwin Investment Advisory's 13F filing for Q1 2021, filed 5 May 2021.